Related references
Note: Only part of the references are listed.Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window
Alexander Gillis et al.
MOLECULAR PHARMACOLOGY (2020)
Current status of opioid addiction treatment and related preclinical research
M. J. Kreek et al.
SCIENCE ADVANCES (2019)
Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats
Kathryn L. Schwienteck et al.
NEUROPHARMACOLOGY (2019)
Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys
Jeremy C. Cornelissen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Drug Binding Poses Relate Structure with Efficacy in the μ Opioid Receptor
Katy J. Sutcliffe et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model
T. W. Grim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays
T. W. Grim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Structural insights into μ-opioid receptor activation
Weijiao Huang et al.
NATURE (2015)
Propagation of conformational changes during μ-opioid receptor activation
Remy Sounier et al.
NATURE (2015)
The clinical analgesic efficacy of buprenorphine
R. B. Raffa et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido) morphinan (NAQ) analogues as potent opioid receptor ligands: Preliminary results on the role of electronic characteristics for affinity and function
Yunyun Yuan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
H. Rollema et al.
NEUROPHARMACOLOGY (2007)
Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists
SS Negus
BIOCHEMICAL PHARMACOLOGY (2006)
Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis
C. A. Tamminga et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2002)
Share Paper
